目的探讨雷贝拉唑联合替普瑞酮治疗慢性胃炎患者的临床疗效。方法选取2013年1月至2014年6月磐石市医院收治的96例慢性胃炎作为研究对象,按随机数字表法将其分为观察组和对照组,各48例。对照组患者口服替普瑞酮,观察组患者在对照组基础上采用雷贝拉唑进行治疗,比较两组患者的临床治疗效果、临床症状改善时间、胃黏膜修复效果、不良反应发生情况及复发率。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);观察组患者腹胀、上腹疼痛、反酸消失时间均明显短于对照组,差异均有统计学意义(均P<0.05);治疗后,观察组患者的胃黏膜组织慢性炎症评分、活动性炎症评分均明显低于对照组,差异均有统计学意义(均P<0.05);随访1年,观察组患者复发率为2.1%(1/48),明显低于对照组的20.8%(10/48),差异有统计学意义(P<0.05)。结论雷贝拉唑联合替普瑞酮治疗慢性胃炎患者临床疗效明显,可加快患者康复进程,降低复发率,提高胃黏膜修复效果,安全性高。 Objective To investigate the clinical efficacy of rabeprazole combined with teprenone in the treatment of patients with chronic gastritis. Methods Ninety-six patients with chronic gastritis admitted from January 2013 to June 2014 in Panshi Hospital were enrolled in this study. According to the random number table, they were divided into observation group and control group, 48 cases each. The patients in the control group were treated with oral teprenone. The patients in the observation group were treated with rabeprazole on the basis of the control group. The clinical effects, clinical symptoms, gastric mucosal repair, adverse reactions and recurrence were compared between the two groups rate. Results The total effective rate of observation group was significantly higher than that of the control group (P <0.05). The observation group had shorter bloating, epigastric pain and disappearance of acid reflux than the control group (All P <0.05). After treatment, the gastric mucosal chronic inflammation score and active inflammation score in the observation group were significantly lower than those in the control group (all P <0.05); after one year of follow-up . The recurrence rate in observation group was 2.1% (1/48), which was significantly lower than that in control group (20.8%, 10/48). The difference was statistically significant (P <0.05). Conclusion Rabeprazole combined with teprenone in patients with chronic gastritis clinical curative effect is obvious, can speed up the patient’s recovery process, reduce the recurrence rate, improve gastric mucosal repair effect, high safety.